Prosthetic Valve Types and Thrombotic Risk
For patients requiring valve replacement, mechanical valves offer superior durability but mandate lifelong anticoagulation with higher thrombotic and bleeding risks, while bioprosthetic valves avoid anticoagulation but deteriorate faster, particularly in younger patients; annuloplasty rings (especially autologous pericardial) preserve native valve function without requiring anticoagulation.
Mechanical Prosthetic Valves
Types and Characteristics
Current-generation mechanical valves include bileaflet designs (St. Jude Medical, CarboMedics) and tilting disk valves (Medtronic-Hall). Older caged-ball valves (Starr-Edwards) are rarely implanted now 1.
Advantages
- Exceptional durability: Essentially lifetime valve function without structural deterioration 1, 2
- No reoperation risk from valve failure in compliant patients 2
- Preferred for younger patients: Recommended for patients <50 years (aortic) and <65 years (mitral position) 1, 3
Disadvantages and Thrombotic Risk
Anticoagulation is mandatory for all mechanical valves to prevent valve thrombosis and thromboembolism 1. The thrombotic risk profile varies by:
Aortic Position (Lower Risk)
- INR target 2.5 (range 2.0-3.0) for current-generation bileaflet/tilting disk valves without additional risk factors 1
- Thromboembolism rate: 0.53% per patient-year with INR 2.0-4.5 1
- Higher INR target 3.0 (range 2.5-3.5) required if risk factors present: atrial fibrillation, prior thromboembolism, hypercoagulable state, older-generation valve, or severe LV dysfunction 1
Mitral Position (Higher Risk)
- INR target 3.0 (range 2.5-3.5) for all mechanical mitral valves 1
- Higher thromboembolism incidence than aortic position 1, 4
- Lower INR ranges associated with reduced survival 1
Bleeding Risk
- Increases significantly with INR >4.0 1
- Adding aspirin 75-100 mg increases bleeding somewhat at INR 2.0-3.5, but becomes excessive at INR 3.0-4.5 4
- Aspirin addition does reduce thromboembolic events but must be weighed against bleeding risk 1, 4
Critical Contraindications
Do not use mechanical valves if: anticoagulation is contraindicated, patient refuses warfarin therapy, or compliance/monitoring is unreliable 1. Newer anticoagulants (DOACs) are not safe or effective for mechanical valves 1.
Bioprosthetic Valves
Types
- Porcine valves (from pig aortic valves)
- Bovine pericardial valves (constructed from cow pericardium)
- Homografts (donor human valves) 5
Advantages
- No long-term anticoagulation required (only aspirin 75-100 mg daily after surgical implantation) 1, 5
- Lower bleeding risk compared to mechanical valves 1, 3
- Excellent hemodynamics, particularly homografts 1
Disadvantages and Structural Deterioration Risk
Age-dependent failure rates are the critical limitation:
Age <50 years:
Age 50-65 years:
Age >65 years:
Thrombotic Risk (Lower but Present)
- First 3 months post-op: Elevated thromboembolic risk, particularly mitral position 4
- Some centers use warfarin (INR 2.0-2.3) for first 3 months, then aspirin long-term 4
- Long-term aspirin may reduce thromboembolism in bioprosthetic valves 4
Annuloplasty Rings
Used for valve repair (not replacement), primarily for mitral and tricuspid regurgitation 5.
Types
Prosthetic Rigid Rings
- Examples: Carpentier-Edwards rigid ring
- Durable synthetic materials
- Disadvantage: May restrict normal annular motion and dynamics 6
Flexible/Semi-rigid Prosthetic Rings
- Allow some physiologic annular motion
- Intermediate between rigid and biological options
Biological Rings (Autologous Pericardial)
- Constructed from patient's own pericardium during surgery
- Superior preservation of mitral annulus dynamics and LV function during exercise 6
- No calcification observed up to 6 years post-surgery 6
- Preferred when feasible for maintaining physiologic valve mechanics 6
Thrombotic Risk
No long-term anticoagulation required for any annuloplasty ring type 5. This is a major advantage over valve replacement.
Decision Algorithm
Age-Based Primary Consideration:
Age <50 years (aortic) or <65 years (mitral):
- Choose mechanical valve unless anticoagulation contraindicated or patient refuses 1, 3
- Accept lifelong anticoagulation burden for durability benefit
Age 50-65 years (aortic) or 65-70 years (mitral):
- Shared decision-making weighing:
- Mechanical: bleeding risk vs. no reoperation
- Bioprosthetic: reoperation risk vs. no anticoagulation
- Consider comorbidities, life expectancy, patient lifestyle/preference 1, 2
Age >65 years (aortic) or >70 years (mitral):
- Choose bioprosthetic valve 1, 3
- Durability exceeds life expectancy; avoid anticoagulation complications
Special Circumstances:
Already on anticoagulation (e.g., atrial fibrillation, prior DVT):
- Consider mechanical valve since anticoagulation already required 3
Women desiring pregnancy:
- Strong consideration for bioprosthetic despite young age, due to warfarin teratogenicity and high thrombotic risk during pregnancy 1, 3
Valve repair possible:
- Always prefer repair over replacement when technically feasible
- Use annuloplasty ring (preferably autologous pericardial if available) 6
- Avoids all prosthesis-related complications
Anticoagulation contraindicated:
- Bioprosthetic valve is mandatory 1
- Includes patients with high bleeding risk, compliance concerns, or geographic/lifestyle barriers to INR monitoring 3
Common Pitfalls
- Assuming DOACs work for mechanical valves: They do not; only warfarin is proven safe 1
- Using same INR target for all mechanical valves: Mitral position requires higher INR (3.0) than aortic (2.5) 1
- Ignoring first 3 months after bioprosthetic implantation: Thromboembolic risk exists early; consider short-term anticoagulation or aspirin 4
- Arbitrary age cutoffs without patient discussion: The 60-70 age range requires individualized assessment, not automatic assignment 1, 2